Brain Cancer

FDA Grants Fast Track Designation to Paxalisib for Patients with Glioblastoma
August 20, 2020

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promoter status who have completed initial radiation with concomitant temozolomide.

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements
March 17, 2020

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.

Racial/Ethnic Disparities in Pediatric Patients with Brain Cancer
March 16, 2020

A population-based analysis found that racial and ethnic disparities in childhood central nervous system tumor survival seem to have their roots at least partially in post-diagnosis factors, possibly due to the lack of access to high quality care, leading to poorer overall outcomes.